117 Broadway
Unit 4
Nedlands, WA 6009
Australia
61 8 9329 3396
https://argenica.com.au
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director | 276,25k | N/D | N/D |
Ms. Emma Waldon | CFO & Company Secretary | N/D | N/D | 1976 |
Prof. Bruno Philip Meloni | Chief Scientific Officer | N/D | N/D | N/D |
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
L'ISS Governance QualityScore di Argenica Therapeutics Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.